PsoriasisPsoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis
Section snippets
Methods
A systematic literature review was performed utilizing PubMed and Medline databases (1996 to August 2009) searching the index terms “tumor necrosis factor alpha inhibitor,” “TNF,” “infliximab,” “etanercept,” “adalimumab,” combined with the terms “psoriasis,” “pustular,” “skin,” “rash,” “palmoplantar,” and “paradoxical.” All relevant articles in English were reviewed, as well as those foreign language journals for which English translation could be obtained. Pertinent secondary references,
Results
Two hundred twenty-one cases were identified by comprehensive literature review. An additional 131 cases were reported in the context of registry data and adverse event reports; these cases were not included in final analysis due to paucity of individual findings and the probability that some of these patients were included in the cases reported in the literature. Of the 221 reported cases, 205 were detailed to an extent allowing inclusion in the final analysis; 2 unpublished cases recently
Discussion
There are currently over 200 described cases of suspected TNF antagonist induced or exacerbated psoriasis in the literature (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81). Following the above data analysis and review of these cases, no
References (109)
- et al.
Potential complications associated with the use of biologic agents for psoriasis
Dermatol Clin
(2007) - et al.
Psoriasis inducida por infliximab: un hecho paradójico [letter]
Med Clin (Barc)
(2006) Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab
Ann Dermatol Venereol
(2007)- et al.
Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases
Ann Dermatol Venereol
(2007) - et al.
Onset or exacerbation of cutaneous psoriasis during TNFα antagonist therapy
Joint Bone Spine
(2008) - et al.
Psoriasis pustulosa inducida por infliximab en una paciente con enfermedad de Crohn [Infliximab-induced pustular psoriasis in a patient with Crohn's disease]
Gastroenterol Hepatol
(2009) - et al.
Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn's sacroiliitis
Clin Gastroenterol Hepatol
(2009) - et al.
Psoriasis secundaria al tratamiento con infliximab y adalimumab en la enfermedad de Crohn [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease]
An Pediatr (Barc)
(2009) - et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
J Am Acad Dermatol
(2008) - et al.
The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study
Gastroenterology
(2005)
Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions
Am J Pathol
Increased sensitivity to interferon-α in psoriatic T cells
J Invest Dermatol
Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris
Lab Invest
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis
Complications and adverse reactions in the use of newer biologic agents
Semin Cutan Med Surg
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
J Rheumatol
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action
Arthritis Rheum
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor-α therapy: results from the British Society for Rheumatology Biologics Register
Ann Rheum Dis
A randomized trial of etanercept as monotherapy for psoriasis
Arch Dermatol
Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?
Ann Rheum Dis
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series
J Rheumatol
Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports
Ann Rheum Dis
Skin reaction to adalimumab
Arthritis Rheum
New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-alpha antagonists: report of 8 cases
Ann Rheum Dis
Psoriasiform eruption induced by infliximab
Ann Pharmacother
Pustular psoriasis induced by infliximab
J Drugs Dermatol
Psoriatic lesions induced by anti-tumor necrosis factor alpha treatment: two cases
Br J Dermatol
Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study
Arthritis Res Ther
Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. [letter]
Arthritis Rheum
Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction
Arthritis Rheum
Onset of flexural psoriasis during infliximab treatment for Crohn's disease
Clin Exp Derm
Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor alpha in the normal palmar eccrine sweat duct?
Br J Dermatol
Pustular skin lesions in patients treated with infliximab: report of two cases
Rheumatol Int
Pustulose palmaire et plantaire chez une patiente traite′e par adalimumab [abstract]
Rev Rhum
Cutaneous modifications during anti-TNF therapy in rheumatoid arthritis [abstract]
Ann Rheum Dis
Psoriasis cutané induit par traitement anti-TNF alpha au cours d'une fasciite éosinophile [abstract]
Rev Rhum
A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents
Ann Rheum Dis
Development of new-onset psoriasis while on anti-TNF alpha treatment
Ann Rheum Dis
The appearance of pustular psoriasis during antitumor necrosis factor therapy
J Clin Rheumatol
Psoriasis after treatment of juvenile idiopathic arthritis with etanercept
Ann Rheum Dis
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists
Ann Rheum Dis
Anti-tumor necrosis factor alpha-induced psoriasis
J Rheumatol
Infliximab associated new-onset psoriasis
J Drugs Dermatol
Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview
Dermatology
Psoriasis onset during infliximab treatment: description of two cases
Rheumatol Int
In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations
Rheumatology
Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy
Eur J Dermatol
Psoriasiform and pustular eruption induced by infliximab
J Dermatol
Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers
Clin Exp Dermatol
Cutaneous side effects in patients with rheumatoid diseases during application of tumor necrosis factor alpha antagonists
Br J Dermatol
Cited by (229)
Paradoxical Psoriasis
2024, Dermatologic ClinicsCutaneous immune-related phenomena in patients with inflammatory arthritides treated with biological therapies: Clinical and pathophysiological considerations
2023, Seminars in Arthritis and RheumatismParadoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?
2023, Journal of Translational AutoimmunityParadoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
2022, Journal of the American Academy of Dermatology
Disclaimers: The opinions or assertions contained herein are those of the authors and are not to be construed as official policy of the Department of the Army, Department of the Air Force, or the Department of Defense.